<DOC>
	<DOCNO>NCT02973971</DOCNO>
	<brief_summary>The present single center clinical chronobiological study 24 subject ( 12 patient mild moderate form Alzheimer 's disease 12 Healthy subject ) aim characterize ADDIA biomarkers : ) blood cell‐based biomarkers measure flow cytometry use proprietary probe specific two targeted biomarkers , beta‐Amyloid ( Aβ ) peptide kinase , b ) circulate biomarkers peripheral body fluid . The biomarkers analyze sample take different time point day , include fast non-fasting condition two period : day 1 day 14 .</brief_summary>
	<brief_title>ADDIA Chronobiological Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria Alzheimer patient group : Signed Informed Consent . Male female subject , 55 85 year inclusive . Specific clinical phenotype AD : Presence early significant episodic memory impairment ( isolate associate cognitive behavioural change suggestive dementia syndrome ) include follow : Gradual progressive change memory function report patient informant 6 month . Objective evidence amnesic syndrome hippocampal type , base significantly impaired performance episodic memory test establish specificity mild moderate AD . Cognitive test ( measure last 3 month ) include MMSE score 12 ≤ MMSE ≤ 25 mild moderate AD , b ) Scores test routinely practice hospital measurement memory cognition shall compatible mild moderate AD . Neuroimaging compatible diagnosis mild moderate AD . Cerebrospinal fluid ( CSF ) biomarkers show least 2 positive level 3 biomarkers ( CSF Aβ1‐42 , Phosphorylated‐Tau Total‐Tau ) . CSF collection data retrospective . Inclusion Criteria healthy control : Signed Informed Consent . Male female subject , 55 85 year inclusive . Normal clinical cognitive score measure use standard neuropsychological test . Normal score neuropsychological test routinely practice hospital measurement memory cognition . No abnormal neuroimaging finding least structural MRI . Any subject sign inform consent form . Any chronic neurodegenerative disease ( vascular dementia , Parkinson 's disease , Creuztfeldt Jacob , Huntington 's disease , etc . ) , acute neurodegenerative disease ( stroke ) , history presence clinically relevant psychiatric history ( schizophrenia , psychosis , major depression , psychiatric disorder ) , chronic inflammatory disease , cancer , major sensory deficit could interfere cognitive assessment ( visual auditory ) , epilepsy . Frequent headache and/or migraine , recurrent nausea and/or vomit ( twice month ) . Blood donation , volume , within 2 month inclusion . Neutropenia ( Neutrophils &lt; 1500/mm3 ) . Thrombocytopenia ( platelet : &lt; 100,000/mm3 , rule EDTA‐induced pseudothrombocytopenia ) .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Blood cell biomarkers , peripheral circulating biomarkers</keyword>
</DOC>